Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 12:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 4,706 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Signs and Symptoms, Respiratory Clear all
Completed Not applicable Interventional Results available

Veterans Integrated Service Network (VISN) 23 Lung Disease Self Management/Case Management Program

NCT00126776
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
case management, usual care
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Not listed
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
5
States / cities
Des Moines, Iowa • Iowa City, Iowa • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2009 · Synced Oct 14, 2026, 12:23 PM EDT
Completed Not applicable Interventional Results available

Improving the Sleep and Circadian Rhythms of Mechanically Ventilated Patients

NCT01284140
View directory record Official record
Conditions
Critical Illness, Sleep Deprivation, Respiratory Failure, Sleep Disorders, Circadian Rhythm
Interventions
Sleep and circadian rhythm promotion, Usual care
Behavioral
Lead sponsor
Brian Gehlbach
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Chicago, Illinois • Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Oct 14, 2026, 12:23 PM EDT
Completed Phase 1 Interventional

Dual Sympathetic Blocks for Patients Experiencing Sympathetically-Mediated Symptoms From Long COVID

NCT05638620
View directory record Official record
Conditions
Post Acute COVID-19 Syndrome, Long COVID, Long Covid19, COVID-19 Recurrent, Post-Acute COVID-19, Post-Acute COVID-19 Infection, SARS-CoV2 Infection, Post Acute Sequelae of COVID-19, Dysautonomia, Dysautonomia Like Disorder, Dysautonomia Orthostatic Hypotension Syndrome, Post COVID-19 Condition, Post-COVID Syndrome, Post COVID-19 Condition, Unspecified, Post-COVID-19 Syndrome
Interventions
stellate ganglion block with 0.5% bupivacaine
Drug
Lead sponsor
Jonathann Kuo, MD
Other
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 14, 2026, 12:23 PM EDT
Completed No phase listed Observational

Biomarkers and Genetic Factors Related to Emphysema

NCT00757120
View directory record Official record
Conditions
Emphysema, Pulmonary Disease, Chronic Obstructive
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
45 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 4, 2018 · Synced Oct 14, 2026, 12:23 PM EDT
Withdrawn No phase listed Observational

Examining the Spasmodic Dysphonia Diagnosis and Assessment Procedure (SD-DAP) for Measuring Symptom Change

NCT02061943
View directory record Official record
Conditions
Spasmodic Dysphonia, Laryngeal Dystonia
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Atlanta, Georgia • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 30, 2016 · Synced Oct 14, 2026, 12:23 PM EDT
Completed Phase 3 Interventional Results available

Efficacy of Dexlansoprazole MR on Heartburn Control in Participants Previously Receiving Twice Daily Proton Pump Inhibitor Therapy

NCT00847808
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Dexlansoprazole MR QD
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
52
States / cities
Hueytown, Alabama • Chandler, Arizona • Sierra Vista, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 14, 2026, 12:23 PM EDT
Completed Not applicable Interventional

Evaluating the Effectiveness of Incentive Spirometry

NCT02952027
View directory record Official record
Conditions
Dyspnea, Respiratory Rate, Oxygen Saturation, Oxygen Requirements, FEV1, FVC, Atelectasis, Pneumonia, Re-intubation, Hospital Length of Stay, Nursing Workload, Incentive Spirometry
Interventions
Use-recording, patient-reminder alarm for incentive spirometry
Behavioral
Lead sponsor
Lifespan
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 14, 2026, 12:23 PM EDT
Recruiting Phase 2 Interventional

Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

NCT05975983
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
INS018_055, Placebo
Drug
Lead sponsor
InSilico Medicine Hong Kong Limited
Industry
Eligibility
40 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
12
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 14, 2026, 12:23 PM EDT
Completed Not applicable Interventional Results available

Suture Closure AFtEr VEIN Access for Cardiac Procedures (SAFE-VEIN) Trial

NCT04632641
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter, Heart Block, Pulmonary Embolism and Thrombosis, Mitral Valve Repair, Sinus Node Dysfunction, Bradycardia, Brady-tachy Syndrome
Interventions
Perclose ProGlide Suture-Mediated Closure System (SMC) - LARGE-BORE PROCEDURES, Figure 8 Suture - LARGE-BORE PROCEDURES
Device · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 14, 2026, 12:23 PM EDT
Completed Not applicable Interventional

Study of Tauroursodeoxycholic Acid for Hepatobiliary Disease in Cystic Fibrosis

NCT00004441
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
tauroursodeoxycholic acid, ursodiol
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
2
States / cities
Denver, Colorado • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 14, 2026, 12:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant

NCT05477108
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Treatment A (BGF MDI HFO with oral activated charcoal), Treatment B (BGF MDI HFA with oral activated charcoal)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 14, 2026, 12:23 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Pranayama Practice on the Autonomic Nervous System

NCT03280589
View directory record Official record
Conditions
Pranayama Effect on Autonomic Nervous System, Respiration Variability Effect on Nervous System
Interventions
Sheetali/Sheekari Pranayama, Sitting Quietly, Deep breathing
Other
Lead sponsor
National University of Natural Medicine
Other
Eligibility
25 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 24, 2023 · Synced Oct 14, 2026, 12:23 PM EDT
Terminated Phase 2 Interventional Results available

Etoposide in Patients With COVID-19 Infection

NCT04356690
View directory record Official record
Conditions
COVID-19
Interventions
Etoposide
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 14, 2026, 12:23 PM EDT
Active, not recruiting No phase listed Observational

Advancing Precision Lung Cancer Surveillance and Outcomes in Diverse Populations

NCT07581379
View directory record Official record
Conditions
Lung Neoplasms, Second Primary Lung Cancer (SPLC), Non-Small Cell Lung Cancer (NSCLC), Stage I-IIIA, Lung Cancer (Diagnosis)
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
Not listed
Enrollment
1,826 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 14, 2026, 12:23 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2)

NCT05281523
View directory record Official record
Conditions
Nasal Polyps
Interventions
Depemokimab (GSK3511294), Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
14
States / cities
Tucson, Arizona • Roseville, California • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 14, 2026, 12:23 PM EDT
Terminated Phase 1 Interventional Results available

Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation

NCT04397796
View directory record Official record
Conditions
COVID
Interventions
BM-Allo.MSC, Placebo
Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Lynwood, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Oct 14, 2026, 12:23 PM EDT
Terminated Phase 2 Interventional

Cholecalciferol Supplementation in Strengthening Inspiratory Muscles in Cholecalciferol-Deficient Patients With Chronic Obstructive Pulmonary Disease

NCT02877641
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Muscle Weakness
Interventions
Cholecalciferol, Laboratory Biomarker Analysis, Multivitamin, Placebo, Questionnaire Administration
Dietary Supplement · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
50 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced Oct 14, 2026, 12:23 PM EDT
Recruiting No phase listed Observational

Vitamin C to Decrease Effects of Smoking in Pregnancy on Infant Lung Function (VCSIP) Longer Term Follow Up

NCT06106646
View directory record Official record
Conditions
Asthma, Pulmonary Function, Wheezing, In Utero Nicotine
Interventions
No active intervention in this protocol (previously randomized to Vitamin C), No active intervention in this protocol (previously randomized to Placebo)
Dietary Supplement · Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
6 Years to 16 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Indianapolis, Indiana • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 14, 2026, 12:23 PM EDT
Completed Not applicable Interventional

Cold Liquids Fed to Preterm Infants: Efficacy and Safety After 10 Minutes of Exposure

NCT02935946
View directory record Official record
Conditions
Deglutition Disorders, Respiratory Aspiration
Interventions
Cold Liquid Barium
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
36 Weeks to 43 Weeks
Enrollment
4,043 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced Oct 14, 2026, 12:23 PM EDT
Completed No phase listed Observational Results available

A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD)

NCT05169424
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Trelegy Ellipta, Stiolto Respimat, Tiotropium + Olodaterol (5/5 mcg), Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg)
Device · Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
9,117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
White Plains, New York
Source: ClinicalTrials.gov public record
Updated Oct 19, 2023 · Synced Oct 14, 2026, 12:23 PM EDT
Completed Not applicable Interventional Results available

FOB in HSCT and Leukemia Patients With Acute Respiratory Symptoms and Pulmonary Infiltrates

NCT01328873
View directory record Official record
Conditions
Pulmonary Infiltrate New
Interventions
Microbiological analysis
Other
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
18 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 14, 2026, 12:23 PM EDT
Completed Phase 2 Interventional Results available

Brain Tissue Oxygen Monitoring in Traumatic Brain Injury (TBI)

NCT00974259
View directory record Official record
Conditions
Severe Traumatic Brain Injury
Interventions
Management protocol based on pBrO2 and ICP values., Management protocol based on ICP values only.
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
10
States / cities
Miami, Florida • Durham, North Carolina • Cincinnati, Ohio + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Oct 14, 2026, 12:23 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing the Clinical Equivalence of Two Mometasone Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

NCT01038427
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
Mometasone furoate 50 mcg/actuation nasal spray (Lek Pharmaceuticals), Mometasone furoate (Nasonex®) 50 mcg/actuation nasal spray, Placebo
Drug
Lead sponsor
Sandoz
Industry
Eligibility
12 Years and older
Enrollment
795 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
8
States / cities
Austin, Texas • Kerrville, Texas • Live Oak, Texas + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 14, 2026, 12:23 PM EDT
Completed Phase 2 Interventional Results available

Study of Dexpramipexole Chronic Sinusitis With Nasal Polyps and Eosinophilia

NCT02217332
View directory record Official record
Conditions
Chronic Sinusitis With Nasal Polyps and Eosinophilia
Interventions
dexpramipexole
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
7
States / cities
Boca Raton, Florida • Baltimore, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Oct 14, 2026, 12:23 PM EDT